Sign in
CompletedNo phase

Effect of Sepsis Adsorption Column on Syndecan-1 and Mortality

Key facts

Who runs it
Oral MENTEŞ
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
91 people enrolled
Started
25 May 2023
Ended
9 Jun 2024
Type of study
Observational, 2 groups
Treatments tested
  • sepsis adsorption column
Record updated
24 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients (Patient or relative) who accepted and signed the informed consent form and approved participation in the study
  • Patients over 18 years of age
  • Patients diagnosed with sepsis/septic shock

Who cannot take part

  • The Informed Voluntary Consent Form has not been signed by him/herself and his/her legal heir
  • Patients with sepsis who died within the first 24 hours after admission to the internal medicine intensive care unit and within the first 24 hours after sepsis diagnosis and within the first 24 hours after administration of sepsis adsorption column
  • Patients in Group-1 who could not receive extracorporeal hemoperfusion for any reason or who could not be started and completed

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This observational, cross-sectional, single-center study aims to investigate the effect of extracorporeal sepsis adsorption column therapy on plasma Syndecan-1 levels and clinical outcomes in patients with sepsis. The study was conducted in the Internal Medicine Intensive Care Unit of Gülhane Training and Research Hospital. Patients were divided into two groups: one group received standard sepsis treatment along with an extracorporeal adsorption column (Biosky® MG350), while the other group received only standard treatment. Clinical and laboratory parameters, including Syndecan-1 levels, were evaluated to assess the potential impact of the adsorption column on sepsis-related outcomes.

The 2 groups in the trial

  • Adsorption Column Used

    Consisted of 43 patients. Sepsis adsorption column used. After the initiation of fluid and antibiotic therapy according to the Surviving Sepsis Campaign 2021 Guidelines, an additional routine sepsis adsorption column (Biosky® MG350) was used within 48-72 hours. Clinical status, response to treatment, and plasma Syndecan-1 levels, among all laboratory variables, were evaluated within the first 24 hours following the filter application.

    Treatment: sepsis adsorption column

  • Standard Sepsis Treatment Only

    Consisted of 48 patients. Sepsis adsorption column not used. Patients receiving only fluid and antibiotic therapy, with clinical status, treatment response, and plasma Syndecan-1 levels, along with other laboratory variables, evaluated within the 48-72 hour period.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of Extracorporeal Sepsis Adsorption Column Use on Plasma Syndecan-1 Level and Mortality in Sepsis Patients
Record updated
24 June 2025